drugset / Trial / NCT00413322
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).
Timeline
- Start
- 2005-09
- Primary completion
- 2008-03
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 300 mg/m2 | Intravenous |
| Subject | Belinostat | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Belinostat | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 250 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 500 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 750 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 1000 mg/m2 | — |